EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) have been recommended as the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring <i>EGFR</i> mutations.